FRIDAY, Dec. 17, 2021 (HealthDay Information)
That is a setback for folks hoping to get their youngest youngsters immunized towards the brand new coronavirus as quickly as attainable.
The pediatric trials used a 3 microgram (mcg) dose of the vaccine — equal to about one-tenth of the dose utilized in grownup pictures. And whereas two 3 mcg doses produced a very good immune response in babies and youngsters between 6 months and a couple of years of age — much like that seen in individuals aged 16 to 25 — they failed to take action within the 2- to 5-year age group, the businesses mentioned in a statement.
The following step? Pfizer-BioNTech says they will attempt a 3rd dose to see if that produces a extra strong response, however they haven’t any plans to attempt any quantity of vaccine above 3 mcg. Kids beneath 5 will get the third dose two months after they’ve acquired their second.
“The objective right here is to know the potential of safety of the third dose,” Jerica Pitts, a spokeswoman for Pfizer, advised The New York Instances. “We’re finding out 3 micrograms right now.”
In a convention name held Friday, Kathrin Jansen, Pfizer’s head of vaccine analysis, mentioned a three-dose routine that works for all ages of children is the objective.
There is a constructing consensus that three doses of vaccine, not two, presents the most effective protection towards the brand new coronavirus, together with newer variants corresponding to Omicron.
In addition to the continued trials in very younger youngsters, Pfizer-BioNTech can also be conducting trials of three doses of 10 mcg of COVID vaccine (that is one-third of the dosage utilized in adults) in youngsters ages 5 by way of 12, the businesses mentioned. They hope to finish the trials and ask for U.S. Meals and Drug Administration authorization of a three-dose vaccine collection in youthful youngsters someday within the spring of 2022.
Kids aged 16 and 17 can already obtain booster pictures of Pfizer vaccine: The FDA authorized that last week.
There have been very uncommon situations of a heart situation known as myocarditis noticed in male adolescents and younger males who’ve acquired mRNA vaccines, prompting investigation into use of decrease doses in youthful age teams.
SOURCES: Pfizer-BioNTech, assertion, Dec. 17, 2021; The New York Instances
Copyright © 2021 HealthDay. All rights reserved.